Limbrel

flavocoxid

(fla-vo-cox-id) ,

Limbrel

(trade name)

Classification

Therapeutic: nonopioid analgesics
Pharmacologic: flavanoids
Pregnancy Category: UK

Indications

Dietary management of osteoarthritis; considered to be a medical food product.

Action

Anti-inflammatory and analgesic properties related to inhibition of prostaglandin synthesis by inhibiting cyclo-oxygenase (not COX-2 selective) and other mediators of inflammation.

Therapeutic effects

Decreased pain/inflammation associated with osteoarthritis, with improved mobility.

Pharmacokinetics

Absorption: Some intestinal conversion prior to absorption, remainder unknown.
Distribution: Unknown.
Metabolism and Excretion: Mostly metabolized by the liver.
Half-life: Unknown.

Time/action profile (analgesic effect)

ROUTEONSETPEAKDURATION
POwithin 1–2 hrunknown12 hr

Contraindications/Precautions

Contraindicated in: Hypersensitivity; Obstetric / Lactation / Pediatric: Not recommended.
Use Cautiously in: History of GI bleeding.

Adverse Reactions/Side Effects

Cardiovascular

  • ↑ BP
  • ↑ in varicose veins

Gastrointestinal

  • GI upset

Dermatologic

  • psoriasis

Interactions

Drug-Drug interaction

None noted.

Route/Dosage

Oral (Adults) 250 mg every 12 hr (up to 250 mg three times daily has been used).

Availability

Capsules: 250 mg

Nursing implications

Nursing assessment

  • Assess pain (note type, location, and intensity), range of motion, degree of swelling, and stiffness in affected joints before and periodically during therapy.

Potential Nursing Diagnoses

Chronic pain (Indications)

Implementation

  • Oral: Administer flavocoxid twice daily.

Patient/Family Teaching

  • Instruct patient to take flavocoxid as directed. Do not increase does without consulting health care professional.

Evaluation/Desired Outcomes

  • Decrease in pain and stiffness, and improved mobility in patients with osteoarthritis.

Limbrel

a trademark for flavocoxid.
Mentioned in ?
References in periodicals archive ?
Flavocoxid is currently available in two commercially marketed medical food products under the supervision of a qualified licensed health-care provider: Limbrel, a medical food available in 250 mg and 500 mg versions through conventional prescription pharmacy fulfillment (Primus Pharmaceuticals Inc.
1 /PRNewswire/ -- Limbrel, the first prescription product developed to safely meet the nutritional requirements of patients with osteoarthritis (OA), is being introduced nationally by Primus Pharmaceuticals, Inc.
Limbrel represents an entirely new approach to managing OA with a breakthrough in patient safety.
After more than eight years in development and one year in limited markets, Limbrel represents a safe and totally new approach for millions of OA patients," said Bruce Burnett, PhD, Director of Medical Education and Scientific Affairs for Primus Pharmaceuticals, and former instructor at Yale University School of Medicine.
announces the issuance of a new composition of matter patent for Limbrel, the first prescription medical food product to safely meet the distinctive nutritional requirements of patients with osteoarthritis (OA).
Limbrel contains flavocoxid, a proprietary composition of natural flavonoid ingredients from the plant sources of Scutellaria baicalensis and Acacia catechu that meet the FDA strict safety standard of Generally Recognized As Safe (GRAS).
In this study, the Limbrel and naproxen groups performed nearly identically, showing significant overall improvements in conventional osteoarthritis efficacy measures, including physician and subject global assessments, and WOMAC, a key measure of mobility, stiffness and joint discomfort," said the lead author Robert Levy, M.
Limbrel is the first prescription product that addresses the metabolic processes of osteoarthritis, using all natural, highly concentrated nutritional (flavonoid) ingredients.
First, in the medical food category, Limbrel (made and patented by Primus Pharmaceuticals, Scottsdale, AZ) is the first prescription product developed to meet the nutritional requirements of patients with osteoarthritis through dual inhibition of arachidonic acid metabolism.
Limbrel contains flavocoxid, a proprietary blend of natural ingredients from phytochemical food source materials.
The company claims that Limbrel delivers antioxidant benefit in a highly concentrated form that cannot be obtained simply by changing one's normal diet.